Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 194541, 10 pages
http://dx.doi.org/10.1155/2015/194541
Review Article

Research Progress on the Role of ABC Transporters in the Drug Resistance Mechanism of Intractable Epilepsy

Division of Pediatric Neurology, Children’s Medical Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China

Received 13 September 2014; Revised 4 March 2015; Accepted 5 March 2015

Academic Editor: Aijun Wang

Copyright © 2015 Jie Xiong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Ramachandran and S. D. Shorvon, “Clues to the genetic influences of drug responsiveness in epilepsy,” Epilepsia, vol. 44, supplement 1, pp. 33–37, 2003. View at Google Scholar · View at Scopus
  2. W. Löscher, “Drug transporters in the epileptic brain,” Epilepsia, vol. 48, supplement 1, pp. 8–13, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Rambeck, U. H. Jürgens, T. W. May et al., “Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy,” Epilepsia, vol. 47, no. 4, pp. 681–694, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. I. Fletcher, M. Haber, M. J. Henderson, and M. D. Norris, “ABC transporters in cancer: more than just drug efflux pumps,” Nature Reviews Cancer, vol. 10, no. 2, pp. 147–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Lee, S. Dallas, M. Hong, and R. Bendayan, “Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations,” Pharmacological Reviews, vol. 53, no. 4, pp. 569–596, 2001. View at Google Scholar · View at Scopus
  6. M. L. Amin, “P-glycoprotein inhibition for optimal drug delivery,” Drug Target Insights, vol. 7, pp. 27–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Sisodiya, W.-R. Lin, B. N. Harding, M. V. Squier, and M. Thom, “Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy,” Brain, vol. 125, no. 1, pp. 22–31, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Löscher and H. Potschka, “Blood-brain barrier active efflux transporters: ATP-binding cassette gene family,” NeuroRx, vol. 2, no. 1, pp. 86–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. S. Hartz, A. Mahringer, D. S. Miller, and B. Bauer, “17-β-Estradiol: a powerful modulator of blood-brain barrier BCRP activity,” Journal of Cerebral Blood Flow & Metabolism, vol. 30, no. 10, pp. 1742–1755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Kannan, K. R. Brimacombe, S. S. Zoghbi et al., “N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier,” Drug Metabolism and Disposition, vol. 38, no. 6, pp. 917–922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Luna-Tortós, M. Fedrowitz, and W. Löscher, “Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1,2 and 5) that are overexpressed in pharmacoresistant epilepsy,” Neuropharmacology, vol. 58, no. 7, pp. 1019–1032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. W. Robey, P. R. Massey, L. Amiri-Kordestani, and S. E. Bates, “ABC transporters: unvalidated therapeutic targets in cancer and the CNS,” Anti-Cancer Agents in Medicinal Chemistry, vol. 10, no. 8, pp. 625–633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Cusatis and A. Sparreboom, “Pharmacogenomic importance of ABCG2,” Pharmacogenomics, vol. 9, no. 8, pp. 1005–1009, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Weiss, J. Rose, C. H. Storch et al., “Modulation of human BCRP (ABCG2) activity by anti-HIV drugs,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 2, pp. 238–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Weiss, D. Theile, N. Ketabi-Kiyanvash, H. Lindenmaier, and W. E. Haefeli, “Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors,” Drug Metabolism and Disposition, vol. 35, no. 3, pp. 340–344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. van de Ven, G. L. Scheffer, R. J. Scheper, and T. D. de Gruijl, “The ABC of dendritic cell development and function,” Trends in Immunology, vol. 30, no. 9, pp. 421–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. R. de Waart, C. C. Paulusma, C. Kunne, and R. P. J. Oude Elferink, “Multidrug resistance associated protein 2 mediates transport of prostaglandin E2,” Liver International, vol. 26, no. 3, pp. 362–368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Rius, W. F. Thon, D. Keppler, and A. T. Nies, “Prostanoid transport by multidrug resistance protein4 (MRP4/ABCC4) localized in tissues of the human urogenital tract,” The Journal of Urology, vol. 174, no. 6, pp. 2409–2414, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Sato, E. Malchinkhuu, Y. Horiuchi et al., “Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes,” Journal of Neurochemistry, vol. 103, no. 6, pp. 2610–2619, 2007. View at Google Scholar · View at Scopus
  20. M. Bauer, R. Karch, M. Zeitlinger et al., “In vivo P-glycoprotein function before and after epilepsy surgery,” Neurology, vol. 83, no. 15, pp. 1326–1331, 2014. View at Publisher · View at Google Scholar
  21. M. Rizzi, S. Caccia, G. Guiso et al., “Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance,” Journal of Neuroscience, vol. 22, no. 14, pp. 5833–5839, 2002. View at Google Scholar · View at Scopus
  22. Z. Xiao, Y. Yan, and X.-F. Wang, “Development of PHT-PB-resistant amygdala-kindled rats and expression of MDR1,” Chinese Journal of Neurology, vol. 32, no. 6, pp. 365–368, 1999. View at Google Scholar · View at Scopus
  23. S. M. Dombrowski, S. Y. Desai, M. Marroni et al., “Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy,” Epilepsia, vol. 42, no. 12, pp. 1501–1506, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Volk, H. Potschka, and W. Löscher, “Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables,” Journal of Histochemistry & Cytochemistry, vol. 53, no. 4, pp. 517–531, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Rosado, S. E. Cross, W. J. Pugh, M. S. Roberts, and J. Hadgraft, “Effect of vehicle pretreatment on the flux, retention, and diffusion of topically applied penetrants in vitro,” Pharmaceutical Research, vol. 20, no. 9, pp. 1502–1507, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Jeub, H. Beck, E. Siep et al., “Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats,” Neuropharmacology, vol. 42, no. 1, pp. 107–116, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Potschka and W. Löscher, “In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats,” Epilepsia, vol. 42, no. 10, pp. 1231–1240, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Gu, T.-N. Gu, and B.-G. Zhao, “Correlation research between seizure frequency and phenobarbital concentration in the cerebrospinal fluid and serum of epilepsy patients,” Journal of Apoplexy and Nervous Diseases, vol. 30, no. 5, p. 467, 2013. View at Google Scholar
  29. A. Lazarowski, G. Sevlever, A. Taratuto, M. Massaro, and A. Rabinowicz, “Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy,” Pediatric Neurology, vol. 21, no. 4, pp. 731–734, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. X.-F. Wang, Y. Lü, L. Huang et al., “Detecting overexpression of P-glycoprotein-multidrug resistance gene in epileptic patients peripheral blood lymphocytes,” Chinese Journal of Neurology, vol. 35, no. 6, pp. 348–350, 2002. View at Google Scholar · View at Scopus
  31. U. Seegers, H. Potschka, and W. Löscher, “Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions,” European Journal of Pharmacology, vol. 451, no. 2, pp. 149–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. U. Seegers, H. Potschka, and W. Löscher, “Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy,” Epilepsy Research, vol. 51, no. 3, pp. 257–268, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. S. M. Sisodiya, J. Heffernan, and M. V. Squier, “Over-expression of P-glycoprotein in malformations of cortical development,” NeuroReport, vol. 10, no. 16, pp. 3437–3441, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Lazarowski, F. Lubieniecki, S. Camarero et al., “Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy,” Pediatric Neurology, vol. 30, no. 2, pp. 102–106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Siddiqui, R. Kerb, M. E. Weale et al., “Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1,” The New England Journal of Medicine, vol. 348, no. 15, pp. 1442–1448, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. B. S. Haerian, H. Roslan, A. A. Raymond et al., “ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis,” Seizure, vol. 19, no. 6, pp. 339–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Furuno, M.-T. Landi, M. Ceroni et al., “Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease,” Pharmacogenetics, vol. 12, no. 7, pp. 529–534, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Sultana and D. A. Butterfield, “Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products,” Neurochemical Research, vol. 29, no. 12, pp. 2215–2220, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Potschka, “Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?” Epilepsia, vol. 51, no. 8, pp. 1333–1347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. P. K. Gill, A. Gescher, and T. W. Gant, “Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and θ,” European Journal of Biochemistry, vol. 268, no. 15, pp. 4151–4157, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Ravizza, B. Gagliardi, F. Noé, K. Boer, E. Aronica, and A. Vezzani, “Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy,” Neurobiology of Disease, vol. 29, no. 1, pp. 142–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. J.-P. Wang, Y.-Q. Cao, and Y.-F. Su, “NF-kappa B activation in peripheral blood mononuclear cells of children with epilepsy,” Chinese Journal of Contemporary Pediatrics, vol. 11, no. 1, pp. 44–46, 2009. View at Google Scholar · View at Scopus
  43. W.-H. Pan, C.-H. Yu, H. Hsuchou, and A. J. Kastin, “The role of cerebral vascular NFκB in LPS-induced inflammation: differential regulation of efflux transporter and transporting cytokine receptors,” Cellular Physiology and Biochemistry, vol. 25, no. 6, pp. 623–630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Löscher and H. Potschka, “Role of multidrug transporters in pharmacoresistance to antiepileptic drugs,” The Journal of Pharmacology and Experimental Therapeutics, vol. 301, no. 1, pp. 7–14, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Potschka, M. Fedrowitz, and W. Löscher, “Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 1, pp. 124–131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Potschka and W. Löscher, “Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain,” NeuroReport, vol. 12, no. 11, pp. 2387–2389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. J. L. Scism, K. M. Powers, A. A. Artru, L. Lewis, and D. D. Shen, “Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study,” Brain Research, vol. 884, no. 1-2, pp. 77–86, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Summers, J. L. Moore, and J. W. McAuley, “Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy,” Annals of Pharmacotherapy, vol. 38, no. 10, pp. 1631–1634, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. X.-F. Wang, Y. Yan, and Y. Lü, “Flunarizine: anticonvulsant activity and reversing overexpresion of P-glycoprotein-multidrug resistance gene in treatment of refractory epileptic patients,” Chinese Journal of New Drugs and Clinical Remedies, vol. 20, no. 5, pp. 363–365, 2001. View at Google Scholar
  50. F. Nicita, A. Spalice, L. Papetti, M. Nikanorova, P. Iannetti, and P. Parisi, “Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study,” Seizure, vol. 23, no. 1, pp. 36–40, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Gennuso, C. Fernetti, C. Tirolo et al., “Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1),” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2470–2475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Pallis, J. Turzanski, Y. Higashi, and N. Russell, “P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype,” Leukemia & Lymphoma, vol. 43, no. 6, pp. 1221–1228, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Xie, G.-J. Shi, and C.-Z. Li, “Effect of Chaihu Shugan Tang on electroencephalogram and expression of multidrug resistance protein P-glycoprotein of refractory epilepsy,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 17, no. 3, pp. 128–131, 2011. View at Google Scholar
  54. L. Wei, A.-M. Li, and R.-C. Luo, “Research progress of multi-drug resistance and reverse of liver cancer,” Journal of China Pharmacy, vol. 20, no. 7, pp. 547–549, 2009. View at Google Scholar
  55. A. H. Schinkel and J. W. Jonker, “Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview,” Advanced Drug Delivery Reviews, vol. 55, no. 1, pp. 3–29, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. H.-Y. Sun, H.-Q. Dai, N. Shaik, and W. F. Elmquist, “Drug efflux transporters in the CNS,” Advanced Drug Delivery Reviews, vol. 55, no. 1, pp. 83–105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. W. M. Pardridge, “Blood-brain barrier biology and methodology,” Journal of NeuroVirology, vol. 5, no. 6, pp. 556–569, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Fricker and D. S. Miller, “Modulation of drug transporters at the blood-brain barrier,” Pharmacology, vol. 70, no. 4, pp. 169–176, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. K. M. Kirschbaum, M. Uhr, D. Holthoewer et al., “Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice,” Neuropharmacology, vol. 59, no. 6, pp. 474–479, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Bauer, A. M. S. Hartz, A. Pekcec, K. Toellner, D. S. Miller, and H. Potschka, “Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling,” Molecular Pharmacology, vol. 73, no. 5, pp. 1444–1453, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Zibell, B. Unkrüer, A. Pekcec et al., “Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition,” Neuropharmacology, vol. 56, no. 5, pp. 849–855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Pekcec, B. Unkrüer, J. Schlichtiger et al., “Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 939–947, 2009. View at Publisher · View at Google Scholar · View at Scopus